[1]
|
《中国心血管健康与疾病报告2021》要点解读[J]. 中国心血管杂志, 2022, 27(4): 305-318.
|
[2]
|
Ndrepepa, G., Braun, S., King, L., et al. (2012) Association of Uric Acid with Mortality in Patients with Stable Coronary Artery Dis-ease. Metabolism, 61, 1780-1786. https://doi.org/10.1016/j.metabol.2012.05.014
|
[3]
|
Wei, F., Sun, N., Cai, C., et al. (2016) Associations between Serum Uric Acid and the Incidence of Hypertension: A Chinese Senior Dynamic Cohort Study. Journal of Translational Medicine, 14, Article No. 110.
https://doi.org/10.1186/s12967-016-0866-0
|
[4]
|
Okazaki, H., Shirakabe, A., Kobayashi, N., et al. (2016) The Prognostic Impact of Uric Acid in Patients with Severely Decompensated Acute Heart Failure. Journal of Cardiology, 68, 384-391. https://doi.org/10.1016/j.jjcc.2016.04.013
|
[5]
|
Yu, W. and Cheng, J.-D. (2020) Uric Acid and Cardio-vascular Disease: An Update from Molecular Mechanism to Clinical Perspective. Frontiers in Pharmacology, 11, Article ID: 582680. https://doi.org/10.3389/fphar.2020.582680
|
[6]
|
Chaudhary, K., Malhotra, K., Sowers, J. and Aroor, A. (2013) Uric Acid-Key Ingredient in the Recipe for Cardiorenal Metabolic Syndrome. Cardiorenal Medicine, 3, 208-220. https://doi.org/10.1159/000355405
|
[7]
|
Furuhashi, M. (2020) New Insights into Purine Metabolism in Metabolic Diseases: Role of Xanthine Oxidoreductase Activity. American Journal of Physiology-Endocrinology and Metabolism, 319, E827-E834.
https://doi.org/10.1152/ajpendo.00378.2020
|
[8]
|
中国高尿酸血症与痛风诊疗指南(2019) [J]. 中华内分泌代谢杂志, 2020(1): 1-13.
|
[9]
|
Virdis, A., Masi, S., Casiglia, E., Tikhonoff, V., Cicero, A.F.G., Ungar, A., et al. (2020) Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality over 20 Years. Hypertension, 75, 302-308.
https://doi.org/10.1161/HYPERTENSIONAHA.119.13643
|
[10]
|
Liu, R., Han, C., Wu, D., et al. (2015) Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis. BioMed Research International, 2015, Article ID: 762820.
https://doi.org/10.1155/2015/762820
|
[11]
|
Klisic, A., Kocic, G., Kavaric, N., Jovanovic, M., Stanisic, V. and Ninic, A. (2018) Xanthine Oxidase and Uric Acid as Independent Predictors of Albuminuria in Patients with Diabetes Mellitus Type 2. Clinical and Experimental Medicine, 18, 283-290. https://doi.org/10.1007/s10238-017-0483-0
|
[12]
|
Kang, D.H., Park, S.K., Lee, I.K., et al. (2005) Uric Acid-Induced C-Reactive Protein Expression: Implication on Cell Prolifera-tion and Nitric Oxide Production of Human Vascular Cells. Journal of the American Society of Nephrology, 16, 3553-3562. https://doi.org/10.1681/ASN.2005050572
|
[13]
|
Masuo, K., Kawaguchi, H., Mikami, H., et al. (2003) Serum Uric Acid and Plasma Norepinephrine Concentrations Predict Subsequent Weight Gain and Blood Pressure Ele-vation. Hypertension, 42, 474-480.
https://doi.org/10.1161/01.HYP.0000091371.53502.D3
|
[14]
|
Bjornstad, P., Laffel, L., Lynch, J., El Ghormli, L., Weinstock, R.S., Tollefsen, S.E., et al. (2019) Elevated Serum Uric Acid Is Associated with Greater Risk for Hyperten-sion and Diabetic Kidney Diseases in Obese Adolescents with Type 2 Diabetes: An Observational Analysis from the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study. Diabetes Care, 42, 1120-1128. https://doi.org/10.2337/dc18-2147
|
[15]
|
Verdecchia, P., Schillaci, G., Reboldi, G., Santeusanio, F., Porcellati, C. and Brunetti, P. (2000) Relation between Serum Uric Acid and Risk of Cardiovascular Disease in Essential Hypertension. The PIUMA Study. Hypertension, 36, 1072-1078. https://doi.org/10.1161/01.HYP.36.6.1072
|
[16]
|
Sanchez-Lozada, L.G., Tapia, E., Soto, V., et al. (2008) Treatment with the Xanthine Oxidase Inhibitor Febuxostat Lowers Uric Acid and Alleviates Systemic and Glomerular Hypertension in Experimental Hyperuricaemia. Nephrology Dialysis Transplantation, 23, 1179-1185. https://doi.org/10.1093/ndt/gfm783
|
[17]
|
Feig, D.I., Soletsky, B. and Johnson, R.J. (2008) Effect of Allopurinol on Blood Pressure of Adolescents with Newly Diagnosed Essential Hypertension: A Randomized Trial. JAMA, 300, 924-932. https://doi.org/10.1001/jama.300.8.924
|
[18]
|
Soletsky, B. and Feig, D.I. (2012) Uric Acid Reduction Rec-tifies Prehypertension in Obese Adolescents. Hypertension, 60, 1148-1156. https://doi.org/10.1161/HYPERTENSIONAHA.112.196980
|
[19]
|
Higgins, P., Walters, M.R., Murray, H.M., et al. (2014) Allopurinol Reduces Brachial and Central Blood Pressure, and Carotid Intima-Media Thickness Progression after Ischaemic Stroke and Transient Ischaemic Attack: A Randomised Controlled Trial. Heart, 100, 1085-1092. https://doi.org/10.1136/heartjnl-2014-305683
|
[20]
|
Fromonot, J., Deharo, P., Bruzzese, L., et al. (2016) Adenosine Plasma Level Correlates with Homocysteine and Uric Acid Concentrations in Patients with Coronary Artery Disease. Canadian Journal of Physiology and Pharmacology, 94, 272-277. https://doi.org/10.1139/cjpp-2015-0193
|
[21]
|
Braga, F., Pasqualetti, S., Ferraro, S. and Panteghini, M. (2016) Hyperuricemia as Risk Factor for Coronary Heart Disease Incidence and Mortality in the General Population: A System-atic Review and Meta-Analysis. Clinical Chemistry and Laboratory Medicine, 54, 7-15. https://doi.org/10.1515/cclm-2015-0523
|
[22]
|
Ai, X.M., Wei, L., Ma, L.L., Chen, H.Y., Zhang, Z.J., Ji, Z.F., et al. (2015) Serum Uric Acid and Its Relationship with Cardiovascular Risk Profile in Chinese Patients with Early-Onset Coronary Artery Disease. Clinical Rheumatology, 34, 1605-1611. https://doi.org/10.1007/s10067-015-2878-1
|
[23]
|
Wang, R., Song, Y., Yan, Y. and Ding, Z. (2016) Elevated Serum Uric Acid and Risk of Cardiovascular or All-Cause Mortality in People with Suspected or Definite Coronary Artery Disease: A Meta-Analysis. Atherosclerosis, 254, 193-199.
https://doi.org/10.1016/j.atherosclerosis.2016.10.006
|
[24]
|
Kimura, Y., Yanagida, T., Onda, A., Tsukui, D., Ho-soyamada, M. and Kono, H. (2020) Soluble Uric Acid Promotes Atherosclerosis via AMPK (AMPActivated Protein Kinase)-Mediated Inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 40, 570-582. https://doi.org/10.1161/ATVBAHA.119.313224
|
[25]
|
Pavlusova, M., Jarkovsky, J., Benesova, K., Vitovec, J., Linhart, A., Widimsky, P., et al. (2019) Hyperuricemia Treatment in Acute Heart Failure Patients Does Not Improve Their Long-Term Prognosis: A Propensity Score Matched Analysis from the AHEAD Registry. Clinical Cardiology, 42, 720-727. https://doi.org/10.1002/clc.23197
|
[26]
|
Huang, H., Huang, B., Li, Y., Huang, Y., Li, J., Yao, H., et al. (2014) Uric Acid and Risk of Heart Failure: A Systematic Review and Meta-Analysis. European Journal of Heart Fail-ure, 16, 15-24. https://doi.org/10.1093/eurjhf/hft132
|
[27]
|
Li, Z., Shen, Y., Chen, Y., Zhang, G., Cheng, J. and Wang, W. (2018) High Uric Acid Inhibits Cardiomyocyte Viability Through the ERK/P38 Pathway via Oxidative Stress. Cellular Physiology and Biochemistry, 45, 1156-1164.
https://doi.org/10.1159/000487356
|
[28]
|
Lin, W.D., Deng, H., Guo, P., Liu, F.Z., Chen, R.Y., Fang, X.H., et al. (2019) High Prevalence of Hyperuricaemia and Its Impact on Non-Valvular Atrial Fibrillation: The Cross-Sectional Guangzhou (China) Heart Study. BMJ Open, 9, e028007. https://doi.org/10.1136/bmjopen-2018-028007
|
[29]
|
Celik, M., Yalcinkaya, E., Yuksel, U.C., Gokoglan, Y., Bugan, B., Kabul, H.K., et al. (2015) Increased Serum Uric Acid Lev-els Are Correlated with Decreased Left Atrial Appendage Peak Flow Velocity in Patients with Atrial Fibrillation. Medical Principles and Practice, 24, 263-268. https://doi.org/10.1159/000373892
|
[30]
|
Black-Maier, E. and Daubert, J.P. (2019) Editorial Commentary: Prevention and Treatment of Atrial Fibrillation: Is Hyperuricemia the Next Target? Trends in Cardiovascular Medicine, 29, 48-49.
https://doi.org/10.1016/j.tcm.2018.07.006
|
[31]
|
Maharani, N., Ting, Y.K., Cheng, J., Hasegawa, A., Kurata, Y., Li, P., et al. (2015) Molecular Mechanisms Underlying Urate-Induced Enhancement of Kv1.5 Channel Expression in HL-1 Atrial Myocytes. Circulation Journal, 79, 2659- 2668. https://doi.org/10.1253/circj.CJ-15-0416
|
[32]
|
White, W.B., Saag, K.G., Becker, M.A., Borer, J.S., Gorelick, P.B., Whelton, A., et al. (2018) Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. The New England Journal of Medicine, 378, 1200-1210.
https://doi.org/10.1056/NEJMoa1710895
|
[33]
|
Wilcox, C.S., Shen, W., Boulton, D.W., Leslie, B.R. and Griffen, S.C. (2018) Interaction between the Sodium-Glu- cose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diu-retic Bumetanide in Normal Human Subjects. Journal of the American Heart Association, 7, e007046. https://doi.org/10.1161/JAHA.117.007046
|
[34]
|
Xin, Y., Guo, Y., Li, Y., Ma, Y., Li, L. and Jiang, H. (2019) Ef-fects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus: A Systematic Re-view with an Indirect Comparison Meta-Analysis. Saudi Journal of Biological Sciences, 26, 421-426. https://doi.org/10.1016/j.sjbs.2018.11.013
|
[35]
|
Wiviott, S.D., Raz, I., Bonaca, M.P., Mosenzon, O., Kato, E.T., Cahn, A., et al. (2019) Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine, 380, 347-357.
https://doi.org/10.1056/NEJMoa1812389
|